This article is more than 5 years old. Information may no longer be current.

Alcon signs contract to place excimer lasers in LCA-Vision's LasikPlus surgery centers

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon Laboratories has signed a 5-year contract with LCA-Vision under which LCA-Vision will place Alcon's Allegretto Wave Eye-Q 400 Hz excimer lasers in all 75 of its LasikPlus vision surgery centers by the end of the third quarter, Alcon announced in a press release.

The contract follows results from a contralateral, prospective, randomized clinical study conducted by LCA-Vision that demonstrated good clinical outcomes using the Allegretto Wave Eye-Q excimer laser compared with other platforms. Based on these results, LCA-Vision made the decision to standardize its laser surgery technology from three laser platforms to two, the release said.

"We are excited about the positive results of this clinical trial, which led to this agreement and the opportunity it provides Alcon to expand our relationship with LCA-Vision," Bill Barton, U.S. area president of Alcon, said in the release. "The study validates the investment we made in WaveLight and clearly demonstrates the quality outcomes achieved by the Allegretto platform."

Alcon acquired the U.S. rights to the Allegretto Wave Eye-Q excimer laser technology through the acquisition of assets from WaveLight AG in February 2008.